Drugs / INR731
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07570979 | May 2026 → Jun 2030 expected | castration-resistant prostate carcinoma | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INR731 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07570979 ↗ |
| Route | Oral | “Oral administration” NCT07570979 ↗ |